Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,401
archived clinical trials in
Alzheimer Disease

An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Neurology Specialists of Monmouth County
mi
from
West Long Branch, NJ
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Neurology Specialists of Monmouth County
mi
from
West Long Branch, NJ
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Integrative Clinical Trials, LLC
mi
from
Brooklyn, NY
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Integrative Clinical Trials, LLC
mi
from
Brooklyn, NY
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Alzheimer's Disease and Memory Disorders Center
mi
from
Buffalo, NY
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Alzheimer's Disease and Memory Disorders Center
mi
from
Buffalo, NY
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Clinilabs, Inc (New York)
mi
from
New York, NY
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Clinilabs, Inc (New York)
mi
from
New York, NY
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
mi
from
New York, NY
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
University of Rochester
mi
from
Rochester, NY
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Alzheimer's Memory Center
mi
from
Charlotte, NC
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Alzheimer's Memory Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
The Christ Hospital
mi
from
Cincinnati, OH
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
The Christ Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Lehigh Valley Hospital
mi
from
Allentown, PA
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Lehigh Valley Hospital
mi
from
Allentown, PA
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Rhode Island Mood & Memory Research Institute
mi
from
East Providence, RI
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Rhode Island Mood & Memory Research Institute
mi
from
East Providence, RI
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Radiant Research
mi
from
Greer, SC
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Radiant Research
mi
from
Greer, SC
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Quillen College of Medicine, East TN State University
mi
from
Johnson City, TN
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Quillen College of Medicine, East TN State University
mi
from
Johnson City, TN
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Senior Adults Specialty Research
mi
from
Austin, TX
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Senior Adults Specialty Research
mi
from
Austin, TX
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Services Center - Houston
mi
from
Houston, TX
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Services Center - Houston
mi
from
Houston, TX
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
University of Utah School of Medicine
mi
from
Salt Lake City, UT
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
University of Utah School of Medicine
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
The Memory Clinic
mi
from
Bennington, VT
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
The Memory Clinic
mi
from
Bennington, VT
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Collaborative Neuroscience Network - CNS
mi
from
Long Beach, CA
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Collaborative Neuroscience Network - CNS
mi
from
Long Beach, CA
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Empire Neurology, PC
mi
from
Latham, NY
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Empire Neurology, PC
mi
from
Latham, NY
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Alzheimer's Research and Treatment Center
mi
from
Lake Worth, FL
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Alzheimer's Research and Treatment Center
mi
from
Lake Worth, FL
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Compass Research
mi
from
The Villages, FL
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Compass Research
mi
from
The Villages, FL
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
The Corvallis Clinic, PC
mi
from
Corvallis, OR
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
The Corvallis Clinic, PC
mi
from
Corvallis, OR
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Texas Health Physicians Group
mi
from
Dallas, TX
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Texas Health Physicians Group
mi
from
Dallas, TX
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Olympian Clinical Research
mi
from
Tampa, FL
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Olympian Clinical Research
mi
from
Tampa, FL
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Community Clinical Research Center
mi
from
Anderson, IN
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Community Clinical Research Center
mi
from
Anderson, IN
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Bio Behavioral Health
mi
from
Toms River, NJ
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Bio Behavioral Health
mi
from
Toms River, NJ
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Roper St. Francis Healthcare
mi
from
Charleston, SC
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Roper St. Francis Healthcare
mi
from
Charleston, SC
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Indiana University School of Medicine
mi
from
Indianapolis, IN
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Indiana University School of Medicine
mi
from
Indianapolis, IN
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Valley Medical Primary Care
mi
from
Centerville, OH
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Valley Medical Primary Care
mi
from
Centerville, OH
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Brain Matters Research
mi
from
Delray Beach, FL
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Brain Matters Research
mi
from
Delray Beach, FL
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Millennium Psychiatric Associates, LLV
mi
from
Saint Louis, MO
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Millennium Psychiatric Associates, LLV
mi
from
Saint Louis, MO
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
St. Louis Clinical Trials, LC
mi
from
Saint Louis, MO
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
St. Louis Clinical Trials, LC
mi
from
Saint Louis, MO
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Ohio State University Medical Center
mi
from
Columbus, OH
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Georgetown University Medical Center
mi
from
Washington,
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Alzheimer's Research Company
mi
from
Manchester, NJ
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Alzheimer's Research Company
mi
from
Manchester, NJ
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Miami Jewish Health Systems
mi
from
Miami, FL
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Miami Jewish Health Systems
mi
from
Miami, FL
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Medical Research Center
mi
from
Miami, FL
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Medical Research Center
mi
from
Miami, FL
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Allied Biomedical Research Institute
mi
from
Miami, FL
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Allied Biomedical Research Institute
mi
from
Miami, FL
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
IMIC
mi
from
Palmetto Bay, FL
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
IMIC
mi
from
Palmetto Bay, FL
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Infinity Clinical Research, LLC
mi
from
Sunrise, FL
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Infinity Clinical Research, LLC
mi
from
Sunrise, FL
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Carman Research
mi
from
Smyrna, GA
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Carman Research
mi
from
Smyrna, GA
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Springfield Neurology Associates, LLC
mi
from
Springfield, MA
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Springfield Neurology Associates, LLC
mi
from
Springfield, MA
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
AdvanceMed Research
mi
from
Lawrenceville, NJ
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
AdvanceMed Research
mi
from
Lawrenceville, NJ
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
SPRI Clinical Trials LLC
mi
from
Brooklyn, NY
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
SPRI Clinical Trials LLC
mi
from
Brooklyn, NY
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
The Medical Group of Texas
mi
from
Fort Worth, TX
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
The Medical Group of Texas
mi
from
Fort Worth, TX
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Southern Neurology
mi
from
Kogarah,
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Southern Neurology
mi
from
Kogarah,
Click here to add this to my saved trials
Behavioral Interventions to Prevent or Delay Dementia
Comparative Effectiveness of Behavioral Interventions to Prevent or Delay Dementia (CEBIPODD)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Behavioral Interventions to Prevent or Delay Dementia
Comparative Effectiveness of Behavioral Interventions to Prevent or Delay Dementia (CEBIPODD)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Behavioral Interventions to Prevent or Delay Dementia
Comparative Effectiveness of Behavioral Interventions to Prevent or Delay Dementia (CEBIPODD)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Florida
mi
from
Jacksonville, FL
Behavioral Interventions to Prevent or Delay Dementia
Comparative Effectiveness of Behavioral Interventions to Prevent or Delay Dementia (CEBIPODD)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Behavioral Interventions to Prevent or Delay Dementia
Comparative Effectiveness of Behavioral Interventions to Prevent or Delay Dementia (CEBIPODD)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Behavioral Interventions to Prevent or Delay Dementia
Comparative Effectiveness of Behavioral Interventions to Prevent or Delay Dementia (CEBIPODD)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo
A Multi-centre, Double-blind, Parallel-group, Randomized Controlled Study to Investigate the Efficacy, Safety and Tolerability of Orally Administered BI 409306 During a 12-week Treatment Period Compared to Placebo in Patients With Alzheimer Disease
Status: Enrolling
Updated:  12/31/1969
Premiere Research Institute
mi
from
West Palm Beach, FL
Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo
A Multi-centre, Double-blind, Parallel-group, Randomized Controlled Study to Investigate the Efficacy, Safety and Tolerability of Orally Administered BI 409306 During a 12-week Treatment Period Compared to Placebo in Patients With Alzheimer Disease
Status: Enrolling
Updated: 12/31/1969
Premiere Research Institute
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo
A Multi-centre, Double-blind, Parallel-group, Randomized Controlled Study to Investigate the Efficacy, Safety and Tolerability of Orally Administered BI 409306 During a 12-week Treatment Period Compared to Placebo in Patients With Alzheimer Disease
Status: Enrolling
Updated:  12/31/1969
Richmond Behavioral Associates
mi
from
Staten Island, NY
Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo
A Multi-centre, Double-blind, Parallel-group, Randomized Controlled Study to Investigate the Efficacy, Safety and Tolerability of Orally Administered BI 409306 During a 12-week Treatment Period Compared to Placebo in Patients With Alzheimer Disease
Status: Enrolling
Updated: 12/31/1969
Richmond Behavioral Associates
mi
from
Staten Island, NY
Click here to add this to my saved trials